Structure Therapeutics Inc.
GPCR
$56.65
$2.905.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.57% | 23.01% | 32.74% | 37.41% | 51.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.06% | 74.18% | 79.36% | 58.52% | 53.96% |
| Operating Income | -18.06% | -74.18% | -79.36% | -58.52% | -53.96% |
| Income Before Tax | -15.11% | -89.91% | -78.02% | -46.70% | -36.73% |
| Income Tax Expenses | 66.13% | 448.55% | 165.71% | 57.92% | 31.36% |
| Earnings from Continuing Operations | -15.24% | -90.58% | -78.17% | -46.73% | -36.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.24% | -90.58% | -78.17% | -46.73% | -36.72% |
| EBIT | -18.06% | -74.18% | -79.36% | -58.52% | -53.96% |
| EBITDA | -17.74% | -74.33% | -79.37% | -58.26% | -53.46% |
| EPS Basic | -7.53% | -65.16% | -39.36% | -10.97% | 7.82% |
| Normalized Basic EPS | -16.61% | -60.42% | -34.37% | -5.25% | 13.70% |
| EPS Diluted | -7.53% | -65.16% | -39.36% | -10.97% | 7.82% |
| Normalized Diluted EPS | -16.61% | -60.42% | -34.37% | -5.25% | 13.70% |
| Average Basic Shares Outstanding | 12.49% | 15.63% | 27.02% | 30.58% | 43.42% |
| Average Diluted Shares Outstanding | 12.49% | 15.63% | 27.02% | 30.58% | 43.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |